ARQT - Arcutis Biotherapeutics, Inc.

QQQ $ 472.45 $ -3.52 (-0.74 %)

DIA $ 416.65 $ -1.34 (-0.32 %)

SPY $ 561.95 $ -3.18 (-0.56 %)

TLT $ 100.91 $ -0.48 (-0.47 %)

GLD $ 237.32 $ -0.66 (-0.28 %)

Previous Close

$ 10.16

Open

$ 10.31

Bid

$ 10.41 x 100

Ask

-- x --

Day's Range

$ 10.26 - $ 10.80

52 Week Range

$ 1.76 - $ 13.17

Volume

1,560,467

Average Volume

Market Cap

1.19B

Beta (5Y Monthly)

$ 0.47

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Arcutis Biotherapeutics Completes Enrollme...
09/05/2024 12:06:46

Assessing Arcutis Biotherapeutics: Insight...
08/28/2024 13:00:26

Jefferies Initiates Coverage On Arcutis Bi...
08/28/2024 12:19:44

Jefferies analyst Kambiz Yazdi initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces P...

Arcutis Biotherapeutics Announces Long-Ter...
08/28/2024 12:07:39

cava-group-posts-strong-q2-results-joins-bilibili-workday-and-other-big-stocks-moving-higher-on-friday

CAVA Group Posts Strong Q2 Results, Joins ...
08/23/2024 14:22:49

titan-machinery-reports-weak-preliminary-results-joins-precigen-gogoro-and-other-big-stocks-moving-lower-in-thursday-pre-market-session

Titan Machinery Reports Weak Preliminary R...
08/15/2024 12:11:53

Needham Reiterates Buy on Arcutis Biothera...
08/15/2024 10:34:31

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Arcutis Biotherapeutics Q2 2024 GAAP EPS $...
08/14/2024 20:01:32

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate ...

Peeling Back The Layers: Exploring Arcutis...
07/30/2024 16:00:49

Needham Reiterates Buy on Arcutis Biothera...
07/30/2024 10:24:06

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Arcutis Launches ZORYVE Cream for Atopic D...
07/29/2024 11:32:19

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inn...

Arcutis Submits Supplemental NDA For ZORYV...
07/23/2024 12:17:08

Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp O...

Arcutis To Host ZORYVE Cream 0.15% FDA App...
07/22/2024 12:06:50

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...

fda-approves-expanded-use-of-arcutis-biotherapeutics-eczema-drug-for-patients-as-young-as-6-years

FDA Approves Expanded Use Of Arcutis Bioth...
07/10/2024 15:23:23

FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged s...

Arcutis Biotherapeutics Stock: A Deep Dive...
07/10/2024 12:00:16

Needham Reiterates Buy on Arcutis Biothera...
07/10/2024 10:26:05

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Trading Halt: Halt status updated at 5:15:...
07/09/2024 21:15:04

Arcutis Biotherapeutics Says FDA Approved ...
07/09/2024 20:55:25

ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been...

Trading Halt: Halted at 4:25:38 p.m. ET - ...
07/09/2024 20:25:42

Arcutis Provides Update On sNDA for Roflum...
07/09/2024 12:33:20

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...